Abstract:

Objective
To study the expressions of CD24 and SLeX in lung cancer tissues,and  evaluate the relation ship with  development and progression of lung cancer.Methods Immunohistochemistry was used to detect the expressions of CD24 and SLeX in 70 specimens of lung cancer.Results The positive expression rates of CD24,SLeX in non-small cell lung cancer tissues were 41.3% and 63.5% respectively，There were no expression and weak expression respectively in small cell lung cancer (SCLC) tissues. The positive rates of CD24,SLeX in adenocarcinoma were  55.9% and 76.5%,respectively,which were higher than those in squamous cell carcinoma (24.1%,48.3%)(P<0.05).In lung adenocarcinoma,aquamous cell carcinoma,there was no correlation between CD24-positive patients with age,gender,smoking index,tumor stage and grade(P>0.05).In lung adenocarcinoma and squamous cell carcinoma,the positive expression rate of SLeX  in stage Ⅲ (83.3%) was higher than that in stage Ⅰ-Ⅱ (55.6%),the positive rate in poor differentiated lung cancer(80.8%) was higher than those in  moderate and well differentiate cancer(51.4%),the positive rate in female patients (76.7%) was higher than that in male patients (51.5%)(all P<0.05).The average survival time of the patients with positive expressions of SLeX and CD24 was significantly lower than that of the patients with negative expressions (P<0.05).Conclusion CD24 and SLeX can  play advance roles in the occurrence and development of lung　cancer ， and they can be used as indicators to judge prognosis in lung cancer.

Key words:  CD24;SLeX;lung neoplasms